KOREAN

Innovation

Collaborations

PH PHARMA

We collaborate with companies based in US and Korea to develop innovative drugs targeting major disease areas such as diabetes.

  • Diabetes Market

AB101

PH PHARMA

AB101 is a once-weekly injectable basal insulin for use in patients with type 1 and type 2 diabetes for the control of hyperglycemia.

Diabetes Market

The global cost for diabetic treatment was US$ 41.7Billion in 2015, and it is expected to reach US$ 66.1Billion by 2022. Diabetes is more common in developed countries with high obesity, and US has the highest prevalence of diabetes among all developed countries. (2015 US diabetic treatment cost: US$ 32BN)